Commercialization and clinical development rights of niraparib. The asset is the rights of development of niraparib, a novel poly ADP-ribose polymerase (PARP), inhibitor, used for the treatment of all tumor types excluding prostate cancer.
What you see here scratches the surface
We’ll help you find what you need
This information is available in the PitchBook Platform. To explore Tesaro (niraparib)‘s full profile, request access.
© 2020 PitchBook Data. All rights reserved. PitchBook is a financial technology company that provides data on the capital markets.